Abstract
Purpose: To evaluate the relationship between the occurrence of optic disc hemorrhages (DH) and glaucoma progression as determined by multiple glaucoma testing modalities. Design: Prospective cohort study. Methods: A longitudinal study was undertaken of 124 open-angle glaucoma patients who had yearly disc photography, visual fields (VFs), spectral-domain optical coherence tomography (SD-OCT), retinal nerve fiber layer (RNFL) thickness scans, and optic nerve volume scans (Spectralis), all performed on the same day over a 5-year period. The minimum distance band (MDB) thickness, a 3-dimensional (3D) neuroretinal rim parameter, was calculated from optic nerve volume scans. Patients were classified as glaucoma progressors or glaucoma nonprogressors using event-based analysis. Results: Of 124 open-angle glaucoma patients, 19 (15.3%) had 1 or more DHs on yearly disc photographs. Presence of a DH was associated with localized 3D neuroretinal rim thickness progression (superior MDB progression; odds ratio: 3.96; P = .04) but not with global or inferior MDB progression (P = .14 and .81, respectively), DP progression (P = .08), VF progression (P = .45), or RNFL global, inferior, or superior progression (P = .17, 26, and .76, respectively). In the majority of patients with MDB progression (14/17 or 82%), the progression was noted before or concurrently with the first instance of DH. Conclusions: Glaucoma progression detected by high-density 3D SD-OCT neuroretinal rim measurements preceded DH occurrence in the majority of patients. These findings support the hypothesis that DHs are indicators of ongoing glaucoma progression rather than discrete events that cause subsequent progression.
Original language | English |
---|---|
Pages (from-to) | 188-198 |
Number of pages | 11 |
Journal | American Journal of Ophthalmology |
Volume | 234 |
Early online date | 29 Jun 2021 |
DOIs | |
Publication status | Published - Feb 2022 |
Bibliographical note
Funding Information:Funding/Support: Teresa C. Chen is supported by a Harvard Catalyst National Institutes of Health award UL1 RR 025758, the Massachusetts Lions Eye Research Fund, an American Glaucoma Society Mid-Career Award, the Fidelity Charitable Fund, Department of Defense Small Business Innovation Research award DHP15-016. Milica A Margeta is supported by NIH/National Eye Instituted grants K12 EY016335 and K08 EY030160, American Glaucoma Society Young Clinician Scientist Award, and Research to Prevent Blindness Career Development Award.
Funding Information:
Funding/Support: Teresa C. Chen is supported by a Harvard Catalyst National Institutes of Health award UL1 RR 025758, the Massachusetts Lions Eye Research Fund, an American Glaucoma Society Mid-Career Award, the Fidelity Charitable Fund, Department of Defense Small Business Innovation Research award DHP15-016. Milica A Margeta is supported by NIH/National Eye Instituted grants K12 EY016335 and K08 EY030160, American Glaucoma Society Young Clinician Scientist Award, and Research to Prevent Blindness Career Development Award. Financial Disclosure: Johannes F. de Boer is the chair of the Scientific Advisory Board of the Center for Biomedical Optical Coherence Tomography Research and Translation (Harvard Medical School), and licenses to NIDEK Inc, Terumo Corp, Ninepoint Medical, and Heidelberg Engineering outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Publisher Copyright:
© 2021 The Author(s)
Funding
Funding/Support: Teresa C. Chen is supported by a Harvard Catalyst National Institutes of Health award UL1 RR 025758, the Massachusetts Lions Eye Research Fund, an American Glaucoma Society Mid-Career Award, the Fidelity Charitable Fund, Department of Defense Small Business Innovation Research award DHP15-016. Milica A Margeta is supported by NIH/National Eye Instituted grants K12 EY016335 and K08 EY030160, American Glaucoma Society Young Clinician Scientist Award, and Research to Prevent Blindness Career Development Award. Funding/Support: Teresa C. Chen is supported by a Harvard Catalyst National Institutes of Health award UL1 RR 025758, the Massachusetts Lions Eye Research Fund, an American Glaucoma Society Mid-Career Award, the Fidelity Charitable Fund, Department of Defense Small Business Innovation Research award DHP15-016. Milica A Margeta is supported by NIH/National Eye Instituted grants K12 EY016335 and K08 EY030160, American Glaucoma Society Young Clinician Scientist Award, and Research to Prevent Blindness Career Development Award. Financial Disclosure: Johannes F. de Boer is the chair of the Scientific Advisory Board of the Center for Biomedical Optical Coherence Tomography Research and Translation (Harvard Medical School), and licenses to NIDEK Inc, Terumo Corp, Ninepoint Medical, and Heidelberg Engineering outside the submitted work. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Funders | Funder number |
---|---|
Fidelity Charitable Fund | DHP15-016 |
Harvard Catalyst National Institutes of Health | UL1 RR 025758 |
National Institutes of Health | |
National Eye Institute | K08 EY030160, K12 EY016335 |
National Eye Institute | |
Research to Prevent Blindness | |
Harvard Medical School | |
Massachusetts Lions Eye Research Fund | |
American Glaucoma Society |